Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.60 |
| ▸ | RECQL | P46063 | 1/20 | 0.57 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.57 |
| ▸ | USP2 | O75604 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.53 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.53 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.53 |
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | THRB | P10828 | 1/20 | 0.51 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.51 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.51 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL47319 | 1.00 | HPGD (0.60) | HPGDRECQLEPHX1USP2SMN1; SMN2 | |
| SCHEMBL1148424 | 0.98 | HPGD (0.58) | HPGDRECQLEPHX1USP2SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL6803311 | 0.98 | HPGD (0.58) | HPGDRECQLEPHX1USP2SMN1; SMN2 | |
| Methane SCHEMBL28191135 | 0.98 | HPGD (0.58) | HPGDRECQLEPHX1USP2SMN1; SMN2 | |
| SCHEMBL27638887 | 0.94 | GPR119 (0.56) | HPGDRECQLEPHX1USP2SMN1; SMN2 | |
| SCHEMBL1096914 | 0.93 | HPGD (0.62) | HPGDRECQLEPHX1USP2SMN1; SMN2 | |
| SCHEMBL28577405 | 0.93 | HPGD (0.54) | HPGDRECQLEPHX1USP2SMN1; SMN2 | |
| SCHEMBL2217466 | 0.93 | HPGD (0.54) | HPGDRECQLEPHX1USP2SMN1; SMN2 | |
| SCHEMBL15107851 | 0.93 | HPGD (0.62) | HPGDRECQLEPHX1USP2SMN1; SMN2 | |
| SCHEMBL13779779 | 0.93 | HPGD (0.62) | HPGDRECQLEPHX1USP2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230142119-A1 | TETRACYCLIC COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-05-11 | — | — | US | disclosed |
| US-20220306578-A1 | TETRACYCLIC COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2022-09-29 | — | — | US | disclosed |
| EP-3613729-A1 | TETRACYCLIC COMPOUNDS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2020-02-26 | — | — | EP | disclosed |
| EP-3345903-B1 | TETRACYCLIC COMPOUNDS | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2019-10-09 | — | — | EP | disclosed |
| EP-3345903-A1 | TETRACYCLIC COMPOUNDS | Chugai Seiyaku Kabushiki Kaisha (JP) | 2018-07-11 | — | — | EP | disclosed |
| EP-2975024-B1 | TETRACYCLIC COMPOUNDS | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2018-03-28 | — | — | EP | disclosed |
| US-20160340308-A1 | TETRACYCLIC COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2016-11-24 | — | — | US | disclosed |
| US-9440922-B2 | Tetracyclic compound | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2016-09-13 | — | — | US | disclosed |
| EP-2441753-B1 | TETRACYCLIC COMPOUND | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2016-03-30 | — | — | EP | disclosed |
| EP-2975024-A1 | TETRACYCLIC COMPOUNDS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2016-01-20 | — | — | EP | disclosed |
| CN-1845734-B | Benzimidazole derivatives and their use as protein kinases inhibitors | ASTEX THERAPEUTICS LTD | 2011-06-22 | — | — | CN | disclosed |
| CN-101796031-A | Heterobicyclic carboxamide derivatives and their pharmaceutical use and compositions | PFIZER | 2010-08-04 | — | — | CN | disclosed |
| CN-101679217-A | N-adamantyl benzamides as 11 beta-hydroxysteroid dehydrogenase inhibitors | HIGH POINT PHARMACEUTICALS LLC | 2010-03-24 | — | — | CN | disclosed |
| CN-101671310-A | Compounds and compositions useful as cathepsin s inhibitors | NOVARTIS AG | 2010-03-17 | — | — | CN | disclosed |
| CN-101600701-A | Arylsulfonamide derivatives and methods of use thereof | WYETH CORP (US) | 2009-12-09 | — | — | CN | disclosed |
| CN-101035768-A | Compounds and compositions as cathepsin S inhibitors | NOVARTIS AG (CH) | 2007-09-12 | — | — | CN | disclosed |
| CN-1845734-A | Benzimidazole derivatives and their use as protein kinases inhibitors | ASTEX THERAPEUTICS LTD (GB) | 2006-10-11 | — | — | CN | disclosed |
| CN-1067883-A | FIBRINOGEN RECEPTOR ANTAGONISTS | MERCK & CO INC (US) | 1993-01-13 | — | — | CN | disclosed |
| CN-1060293-A | Fibrinogen receptor anlagonists | MERCK & CO INC (US) | 1992-04-15 | — | — | CN | disclosed |
| CN-1060096-A | FIBRINOGEN RECEPTOR ANLAGONISTS | MERCK & CO INC (US) | 1992-04-08 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230142119-A1 | TETRACYCLIC COMPOUND | ALK, TTR, ACVR1 | HPGD 4633/4885RECQL 3641/4885EPHX1 2261/4885 |
| US-20220306578-A1 | TETRACYCLIC COMPOUND | ALK, TTR, ACVR1 | HPGD 4633/4885RECQL 3641/4885EPHX1 2261/4885 |
| US-20160340308-A1 | TETRACYCLIC COMPOUND | ALK, TTR, ACVR1 | HPGD 4633/4885RECQL 3641/4885EPHX1 2261/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.